Effect of Statin Therapy on C-reactive Protein Levels in Patients With Chronic Obstructive Lung Disease (COPD)
- Registration Number
- NCT00655993
- Lead Sponsor
- VA Loma Linda Health Care System
- Brief Summary
Hypothesis for this pilot study is that simvastatin will lower the levels of CRP and ET-1 in COPD patients.
- Detailed Description
Patients with chronic obstructive lung disease (COPD) have an ongoing systemic inflammation, which can be assessed by measuring C-reactive protein (CRP). CRP is found to be a strong and independent predictor of future COPD outcomes. Statins are a class of cholesterol lowering drugs that decrease mortality from cardiovascular disease and stroke. In addition, they have anti-inflammatory, anti-thrombotic and immunomodulatory properties. Statins lower C-reactive protein by the ability to reduce the production of interleukin (IL)-6, the cytokine that activates the acute phase CRP response.
Thus the rationale for this study is to evaluate effect of statins on the levels of CRP and ET-1 in COPD patients.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 30
- Medically optimized COPD patients
- Age 40-79 years.
- serum CRP levels >3mg/l
- Current smoker
- COPD exacerbation in the last 2 months.
- Active hepatic or severe renal dysfunction.
- connective tissue disease, chronic inflammatory disease, malignancy, any acute illness, leukocytosis (>10,000 white blood cells) or thrombocytosis (>450,000 platelets).
- Recent h/o myocardial infarction, angina in the last 6 months.
- Pregnancy.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description 1 simvastatin placebo drug 2 simvastatin simvastatin
- Primary Outcome Measures
Name Time Method serum CRP levels 9 weeks
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
VA Loma Linda Health Care System
🇺🇸Loma Linda, California, United States